Baseline Characteristics and Histologic Diagnoses and Stage in the ACCELERATE and Reference Groups
NSCLC, pleural effusion, death, melanoma, liver lesion, plasmacytoma, lung cancer, Hodgkin lymphoma, Lung Cancer
PLEURAL EFFUSION, MELANOMA, UTERINE LEIOMYOSARCOMA, PROSTATE, MESOTHELIOMA, ONCOLOGY, ENDOMETRIAL ADENOCARCINOMA, PLASMACYTOMA, SMALL CELL LUNG CANCER, HODGKIN LYMPHOMA, BONE LESION, LUNG, CARCINOMA OF UNKNOWN PRIMARY, LUNG CANCER, BONE ISLAND, METASTASES, LUNG CANCER, GASTROINTESTINAL NEUROENDOCRINE CARCINOMA, NSCLC, BENIGN CYSTS, DIFFUSE LARGE B-CELL LYMPHOMA
ACCELERATE, Accelerating Lung Cancer Diagnosis Through Liquid Biopsy; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; NOS, not otherwise specified; NSCLC, non–small cell lung cancer.Not documented in the ACCELERATE cohort: ethnicity (n = 24). ECOG performance status and ethnicity were not systematically collected in the historical Lung Rapid Assessment and Management Program cohort.A total of 5 patients did not undergo tissue biopsy: 3 declined, 1 did not tolerate procedure, and 1 underwent rapid deterioration and death before tissue biopsy was done.A total of 18 patients with non–lung cancer diagnoses including diffuse large B-cell lymphoma (n = 4); thoracic metastases from breast, prostate, and gastrointestinal neuroendocrine carcinoma (2 each); gastrointestinal stromal tumor; Hodgkin lymphoma; carcinoma of unknown primary; melanoma; mesothelioma; plasmacytoma; endometrial adenocarcinoma; and uterine leiomyosarcoma (1 each).A total of 3 patients with stage IA NSCLC in the ACCELERATE cohort: 1 with pleural effusion (later determined to be nonmalignant), 1 with suspicious liver lesion (later determined to be benign cysts), and 1 with suspicious bone lesion (benign bone island).